Rick Simpson Oil in Australasia: The Complete Evidence-Based Guide by OilWell Cannabis

G’day, Australasia. We see you. From the sun-scorched Outback to the misty fjords of Aotearoa, from the Pacific Island communities battling chronic pain with limited access to specialists, to the cancer wards in Sydney and Auckland where patients are told they’ve exhausted their options — we see you. We built this guide because people across Australia, New Zealand, and the Pacific Islands are searching for honest answers about Rick Simpson Oil, and most of what exists online is either hype-driven marketing or outdated black-market mythology. We’re here to fix that.

We’re OilWell Cannabis, a Houston-based company founded by Colin Valencia, a man who grew up in one of America’s most dangerous border regions, taught himself software engineering at Baylor College of Medicine, and built a cannabis company because conventional medicine failed him, failed his dog Bentley, and continues to fail millions of people who deserve better. We’ve been featured seven times by ABC13 Houston’s news team between 2019 and 2023 — not because we paid for coverage, but because when Texas needed a credible voice on cannabis law, product safety, and community health, journalists kept coming back to us. That’s the kind of credibility you can verify, not buy.

This guide contains everything: the real history of Rick Simpson Oil (RSO), the evidence record for every cannabinoid and terpene in our formulas, our complete open-source recipes so you can make your own if you can’t afford ours, and — most importantly — the honest limitations of what cannabis can and cannot do. We don’t sell hope. We sell transparency, and we ship it legally to Australasia under the 2018 Farm Bill framework.

Who Was Rick Simpson, and Why Does His Story Matter to Australasia?

Rick Simpson was born in 1949 in Amherst, Nova Scotia, Canada. He wasn’t a doctor, scientist, or medical researcher — he was a power engineer and maintenance worker, a blue-collar tradesman whose life changed in 1997 when he fell from scaffolding at a hospital in Moncton. The aftermath included persistent tinnitus, dizziness, and post-concussion symptoms that conventional medicine couldn’t resolve. The medications prescribed either failed or made things worse. When he asked his doctor about cannabis, the request was refused.

Sound familiar, Australia? How many of you have been to a GP in Perth or Brisbane, described chronic pain after a workplace injury, and been handed a prescription for opioids with no discussion of cannabinoid alternatives? How many New Zealanders have faced the same dismissal? Simpson’s experience mirrors what countless Australasians endure daily — a medical system that often treats cannabis as a punchline rather than a legitimate therapeutic option.

Simpson’s pivotal moment came in 2003 when he claimed three bumps on his arm, diagnosed as basal cell carcinoma, disappeared after applying concentrated cannabis oil. Important context: no independent medical verification, no biopsy confirmation, no peer-reviewed documentation exists. This was personal testimony, not clinical evidence. Yet that story, amplified by the 2005 documentary Run From the Cure, launched a global movement. The film was distributed freely online and became foundational in cannabis communities worldwide — including here in Australasia, where patients in remote Northern Territory communities or small South Island towns first learned about RSO through that same documentary.

Traditional RSO Protocol: The 60-Gram Regimen

Simpson’s core recommendation was consuming 60 grams of oil over approximately 90 days. Here’s exactly what that entailed:

Week 1: Start with a dose the size of half a grain of rice (10-15mg) three times daily. Total daily intake: 30-45mg.

Weeks 2-5: Double the dose every four days, building tolerance. Target: 1 gram (1,000mg) per day by week five, divided into three doses.

Weeks 5-12: Maintain 1 gram daily until the full 60 grams are consumed.

Administration: Primarily sublingual/oral. Topical for skin lesions. Inhalation acknowledged for symptom relief but not as primary treatment.

Post-protocol: Maintenance dose of 1-2 grams monthly.

Critical context for Australasia: At peak dosing, patients consumed roughly 600-900mg of delta-9 THC daily — far exceeding anything studied in controlled clinical settings. The FDA-approved synthetic THC drug dronabinol is typically dosed at 2.5 to 20mg per day. Consuming 600-900mg daily carries serious risks: severe intoxication, impairment, anxiety, panic, tachycardia, hypotension, and cannabis use disorder. For cancer patients in Melbourne or Auckland who are medically complex, using unregulated oil as primary treatment introduces harm beyond the oil itself.

Traditional RSO had no standardization. Every batch differed. No lab testing. No contaminant screening. The extraction used naphtha or isopropyl alcohol — not food-grade solvents. Residual solvent risk was real and unverifiable.

Traditional RSO vs. OilWell’s Modern Formulation

Our Formulas: Complete Open-Source Transparency

We publish everything. If you can’t afford our products, make your own. That’s not marketing — it’s our core philosophy, inherited from Rick Simpson’s free-distribution model but adapted for the modern era.

RSO Sublingual Oil Formula

$129.99 | 30mL bottle | 553mg/mL | ~40-60 doses

Terpene Profile (5% live terpenes):
Limonene (citrus-bright), Myrcene, Caryophyllene (pepper/spice), Pinene (forest-fresh), Linalool (lavender), Humulene (earthy/woody), Terpinolene (piney/fruity)

Base: Organic MCT oil
Onset: 15-45 minutes (sublingual)
Duration: 4-6 hours
Bioavailability: 13-19% (partially bypasses first-pass liver metabolism)

RSO Vape Cartridge Formula

$49.99 | 1g cartridge | 510-thread compatible

Terpene Profile: Same 5% live terpene blend as sublingual oil
Onset: 1-2 minutes (fastest delivery)
Duration: 2-4 hours
Bioavailability: 10-35% (variable by inhalation technique)
Auto-decarboxylation: THCa converts to delta-9 THC instantly at vaping temperature (400-450°F)

The Evidence Record: What Science Actually Says

We don’t cherry-pick studies. We evaluate every compound using the same hierarchy: human clinical trials first, then systematic reviews, then institutional summaries, then preclinical literature. Here’s what that means for each cannabinoid in our formula.

CBD (4,500mg in sublingual formula)

Strongest evidence: Rare epilepsies. The FDA approved Epidiolex for specific seizure disorders — that’s the gold standard human evidence [1][2].

Emerging evidence: A 2024 systematic review of 316 participants across eight studies found statistically significant anxiolytic effects, but authors stressed the clinical sample remains limited [3]. For pain, a 2024 review concluded the literature is promising but heterogeneous, with trial quality limiting broad analgesic claims [4]. Sleep research is methodologically weak, with few objective assessments [5].

Safety concerns: 2023 systematic review found real signals for liver enzyme elevation and possible drug-induced liver injury, especially relevant for concentrated oral products and polypharmacy settings [6]. NCCIH flags diarrhea, sleepiness, appetite changes, mood effects, and drug interactions [1].

For Australasia: If you’re in Australia considering CBD for chronic pain or anxiety, understand that while the evidence is evolving, it’s not yet as robust as pharmaceutical marketing suggests. Consult with your GP, especially if you’re on other medications.

CBG (3,000mg in sublingual formula)

Evidence profile: Mostly preclinical and review-level. A 2021 pharmacology review noted CBG is being sold commercially while the evidence base remains thin — claims outrun science [7].

Pharmacology: CBG interacts with cannabinoid receptors, alpha-2 adrenoceptors, and 5-HT1A signaling, making it mechanistically interesting but not clinically established [7][8].

Potential areas: Neurologic disorders, inflammatory bowel disease, antibacterial activity — but these are hypotheses, not proven therapies [7][8].

For Australasia: CBG is the “next big thing” in cannabis marketing across Sydney dispensaries and Auckland wellness shops. We include it because the pharmacology is plausible and we’re committed to full-spectrum formulas, but we’d never claim it’s a proven treatment. It’s promising, not proven.

Delta-8 THC (6,000mg in sublingual formula)

Evidence profile: Pharmacologically relevant and psychoactive, but much less clinically characterized than delta-9 THC [9].

Pharmacology: 2022 review concluded delta-8 and delta-9 have broadly similar behavior. Delta-8 is a partial CB1 agonist, less potent than delta-9, likely due to weaker CB1 affinity [9].

Safety concerns: 2023 scoping review noted adverse consequence reports and emphasized regulatory/product-quality concerns [10]. Manufacturing context shows delta-8’s commercial interest is tied to stability and easier synthesis, not plant abundance [11].

For Australasia: Delta-8’s legal status varies. In Australia, it’s treated similarly to delta-9 THC. In New Zealand, it’s controlled. Always verify your local laws before ordering. We ship with full COAs, but you accept customs responsibility.

Delta-9 THC (90mg in sublingual formula)

Evidence profile: Strongest human evidence among psychoactive cannabinoids, but also clearest adverse-effect burden [1][13]-[15].

Institutional support: NCCIH identifies THC-containing medicines as relevant for chemo nausea, HIV/AIDS appetite, and some MS/pain outcomes [1].

Pain evidence: 2022 systematic review found high-THC products may provide short-term pain benefit but increase dizziness, sedation, nausea, and discontinuation [13].

Mental health risk: 2025 systematic review found consistent unfavorable associations with psychosis/schizophrenia and cannabis use disorder, with concerning signals for anxiety/depression in non-therapeutic settings [15].

For Australasia: Our formula contains only 90mg total delta-9 THC — 3mg/mL. At Simpson’s peak dosing (600-900mg/day), you’d need to consume 200-300mL of our oil. We deliberately minimized delta-9 THC while preserving THCa for patient-controlled activation. This is harm reduction through formulation.

THCa (1,500mg in sublingual formula)

Evidence profile: Important chemically, low on direct human therapeutic evidence [12].

Key distinction: THCa itself is non-psychoactive, but converts to THC with heat (260°F for 45-60 minutes) or over time during storage [12].

Research status: In vitro and rodent literature suggest anti-inflammatory (COX-2 inhibition), immunomodulatory, neuroprotective (PPARγ agonism), and antineoplastic possibilities — not human outcomes [12].

For Australasia: This is our innovation. You can use the oil raw for daytime anti-inflammatory effects without impairment, or decarboxylate it at home for full psychoactive potency. One product, three usage modes. That’s patient-controlled medicine.

CBN (750mg in sublingual formula)

Evidence profile: Weakest in this formula. Marketing has moved ahead of data [12][16][17].

Sleep claims: 2021 review screened 99 human-study abstracts and found NO clinical trials using validated sleep questionnaires or polysomnography to substantiate sleep claims [16]. 2024 updated review concluded cannabinoid sleep research still doesn’t match real-world use [17].

For Australasia: We include 750mg CBN (25mg/mL) because the preclinical rationale is interesting and customers expect it in “sleep” formulas. But we’ll never claim it’s a proven sleep aid. The evidence doesn’t support that, and we won’t lie to you.

CBC (750mg in sublingual formula)

Evidence profile: Emerging, intriguing, overwhelmingly preclinical [18][19].

Pharmacology: 2024 review notes distinct pharmacodynamics/kinetics from other cannabinoids, highlighting antinociceptive, antibacterial, and anti-seizure potential [18].

Safety caveat: Same review notes over-the-counter CBC products are being sold despite little evidence establishing clinical efficacy or safety [18].

For Australasia: Another promising minor cannabinoid that deserves research. We include it for full-spectrum rationale, not because it’s proven.

Terpenes: The Aromatic Dimension

Our formula includes 5% live terpenes with a defined seven-terpene profile. Here’s what the evidence actually says.

Limonene (citrus-bright)

Evidence: Mostly review/preclinical. 2021 review describes antioxidant, anti-inflammatory, cardioprotective, gastroprotective activities — but from nonhuman/non-cannabis literature [21].

Safety note: Limonene oxidation products (hydroperoxides) are contact allergens relevant in patch-testing [22].

For Australasia: If you’ve smelled fresh lemon myrtle in Queensland or used citrus cleaning products in Wellington, you know limonene. It’s bioactive, but cannabis-specific therapeutic claims are premature.

Myrcene

Evidence: Very limited human evidence [20][23]. 2021 review explicitly states human studies are lacking [23].

Caution: Often marketed as a proven sedative explaining “couch-lock.” That’s stronger than current evidence supports.

Caryophyllene (pepper/spice)

Evidence: Most mechanistically interesting terpene — selective CB2 receptor agonist [24]. Makes it pharmacologically unique among terpenes.

Research themes: Anti-inflammatory, immunomodulatory, neuroprotective, gastroprotective — but human confirmation limited [24].

For Australasia: If you’ve tasted peppery Tasmanian mountain pepper or New Zealand kawakawa, you’ve encountered caryophyllene’s aromatic cousins. It’s the strongest candidate for cannabinoid-system significance among terpenes.

Pinene (forest-fresh)

Evidence: Promising preclinical, weak human confirmation [20][25]. 2021 review found antioxidant, anti-inflammatory, neuroprotective signals but emphasized lack of clinical trials [25].

Caution: Claims about memory enhancement or counterbalancing THC cognitive effects remain hypotheses.

Linalool (lavender)

Evidence: Substantial preclinical interest, limited direct clinical confirmation [20][22][25][26]. 2021 brain-health review found enough signal to justify investigation but lacked robust human trials [25].

Safety: Oxidized linalool hydroperoxides are recognized allergens [22].

For Australasia: Lavender farms in Victoria and Marlborough produce beautiful essential oils. Linalool’s calming reputation is cultural, not yet clinical.

Humulene (earthy/woody)

Evidence: Early stage. 2024 scoping review found broad preclinical evidence, some rodent work suggesting cannabimimetic properties via CB1 and adenosine A2a pathways [27].

For Australasia: Humulene is in hops — connects to Australia’s craft beer culture and New Zealand’s hop-growing regions. But clinical claims remain premature.

Terpinolene (piney/fruity)

Evidence: Least clinically characterized. 2021 systematic review of 57 studies concluded evidence dominated by in silico, in vitro, and animal studies [28].

The Decarboxylation Choice: Your Power

This is what makes our product revolutionary for Australasia. You control the psychoactivity.

Raw (No Heat): All 1,500mg THCa stays non-psychoactive. Use during the day, work, drive, parent — zero impairment. Harnesses THCa’s potential COX-2 anti-inflammatory and PPARγ neuroprotective activity [12].

Fully Activated (Home Decarb): Heat at 260°F (125°C) for 45-60 minutes. Converts 1,500mg THCa → ~1,315mg delta-9 THC. Combined with existing 90mg = ~1,405mg total delta-9 THC. Plus 6,000mg delta-8 THC. This matches traditional illegal RSO potency — legally, because you control the activation.

Partial Decarb: Transfer a portion to an oven-safe container, decarb only what you need, preserve the rest raw. Precision control.

Vape (Auto-Decarb): Every puff instantly converts THCa to delta-9 THC at 400-450°F. Fastest relief for breakthrough symptoms.

The conversion ratio: 1mg THCa = 0.877mg delta-9 THC after decarboxylation (loses CO₂ molecule).

For a nurse in Brisbane working a 12-hour shift: use raw during the day, no impairment. For a cancer patient in Christchurch needing nighttime relief: decarb for full potency. For a veteran in Perth with PTSD flashbacks: vape for 1-2 minute onset. One product, infinite personalization.

Safety First: What Australasia Needs to Know

Legal Status: Our products contain less than 0.3% delta-9 THC at point of sale, making them Farm Bill compliant and legal to ship to most Australasia jurisdictions. However, laws vary:

• Australia: Hemp-derived products with <0.3% delta-9 THC are generally legal for import, but states may have additional restrictions. Check Therapeutic Goods Administration (TGA) requirements.
• New Zealand: Hemp products are legal if they meet the Misuse of Drugs (Hemp) Regulations. Our COAs provide documentation.
• Pacific Islands: Laws vary significantly. You accept customs responsibility. We provide full documentation, but verify local regulations before ordering.

Age Requirement: 21+ for all RSO products.

Drug Testing: THCa in raw form will not trigger standard THC tests. Decarboxylated THCa and delta-8 THC will. Be honest with employers, especially in safety-sensitive roles in Australian mining or New Zealand transportation sectors.

Pregnancy/Nursing: Do not use. NIH warnings are clear on pregnancy-related concerns [1].

Liver Health: Our CBD dose (150mg/mL) is substantial. If you have liver conditions or take medications metabolized by CYP450 enzymes (common in Australia/NZ), consult your doctor. The 2023 liver injury meta-analysis is real [6].

Mental Health: If you have a history of psychosis, schizophrenia, or severe anxiety, approach psychoactive cannabinoids cautiously. The 2025 high-THC mental health review found consistent unfavorable associations [15]. Our low delta-9 THC design is intentional harm reduction.

Operating Machinery: Do not drive or operate heavy machinery after consuming activated (decarbed) product. Australia’s strict cannabis DUI laws and New Zealand’s workplace safety regulations are not worth risking.

How to Use Our RSO in Australasia: Condition-Specific Context

Important: These are informed contexts, not prescriptions. Consult your healthcare provider. Our formulas have not been evaluated by the FDA or TGA and are not intended to diagnose, treat, cure, or prevent disease.

Chemotherapy-Related Nausea & Appetite Support

• Pre-chemo: 0.5-1.0mL sublingual 1 hour before treatment
• Breakthrough nausea: 2-3 vape puffs (1-2 minute onset)
• Post-chemo: 0.5mL sublingual every 6 hours as needed
• Sleep: 1.0-2.0mL sublingual before bed (delivers 25-50mg CBN)
• Evidence: delta-8 antiemetic [9], delta-9 nausea evidence [1][13], CBD anxiolytic buffering [3]

Chronic Pain (Fibromyalgia, Arthritis, Neuropathy)

• Daytime: 0.3-0.5mL raw sublingual — anti-inflammatory without impairment
• Nighttime: 0.5-1.0mL decarbed sublingual — pain relief + CBN sleep support
• Breakthrough: Vape as needed
• Evidence: CBD pain [4], delta-9 pain [13], caryophyllene CB2 agonism [24], THCa COX-2 inhibition [12]

Sleep Support

• Before bed: 1.0-2.0mL sublingual
• 2.0mL = 50mg CBN (investigated in 2024 sleep literature [16][17])
• 1.0mL = 25mg CBN (above 20mg threshold associated with reduced sleep disturbance)

Anxiety & Stress

• Daytime functional: 0.3mL raw sublingual — CBD + CBG without impairment
• Nighttime: 1.0mL sublingual — full profile including CBN
• Evidence: CBD anxiety [3], CBG pharmacology [7][8], limonene entourage [20]

General Titration Principle: Start low, go slow. Begin 0.25-0.5mL sublingual, assess effects over 2-3 hours before increasing. Individual responses vary by weight, metabolism, tolerance, and concurrent medications.

Delivery to Australasia: How You Get It

We operate the only same-day RSO delivery system in Houston, but for Australasia, we ship worldwide with full documentation.

Australia & New Zealand Shipping:

• USPS Priority Mail International (6-10 business days)
• FedEx/UPS International (3-5 business days)
• Discreet packaging, no cannabis branding
• Full COAs, customs documentation, and receipts included
• You accept all customs and legal responsibility — verify your local laws before ordering

Pacific Islands Shipping:

• Same international options, though delivery times vary by island infrastructure
• We recommend FedEx/UPS for tracking reliability in remote regions

Texas Medical Center Free Delivery:
Why mention this for Australasia? Because it demonstrates our values. We deliver free to MD Anderson, Memorial Hermann, Texas Children’s — the world’s largest medical complex with 10 million patient visits annually. We prioritize accessibility for the sickest patients. That same philosophy extends to you in Australasia: we keep margins reasonable ($129.99 for 16,590mg total cannabinoids is $7.83 per 1,000mg), publish our formulas, and ship globally because access should transcend borders.

Why Our Formulas Diverge: The Evidence-Based Evolution

We respect Rick Simpson’s legacy, but we part ways where the evidence demands it:

Multi-Cannabinoid Approach
Simpson used single-strain indica. We use seven cannabinoids because entourage-effect literature suggests benefit from diversity, even though robust clinical proof of whole-formula synergy remains limited [20][29].

Terpene Preservation
Traditional RSO destroyed terpenes. We include 5% live terpenes because bioactivity is plausible and supported preclinically, even if human confirmation is developing [20]-[28].

THCa as Separate Ingredient
Simpson fully decarbed everything. We preserve 1,500mg THCa because the literature suggests non-psychoactive bioactivity lost during conversion [12].

Reduced Delta-9 Dominance
Traditional RSO was 60-90% delta-9 THC. We use only 90mg total delta-9 THC while distributing the remaining content across CBD, CBG, delta-8, THCa, CBN, and CBC. This reflects broader cannabinoid research, not single-compound obsession.

Product Format Innovation
Simpson had one format. We offer sublingual oil for sustained relief and vape for breakthrough moments, acknowledging different pharmacokinetic profiles [14].

Media Recognition: Why ABC13 Keeps Coming Back

Between 2019-2023, ABC13 Houston featured us seven times across five different reporters. No other Houston cannabis operator matches that frequency or breadth. Here’s what they documented:

September 2019: CBD business boom. Colin’s foundational quote: “I’m not trying to sell people snake oil… there’s enough research that people just need to know and try and have the best possible version.”

March 2021: Decriminalization and ecosystem building. Helped entrepreneur Jonathan Pina launch High Maintenance Edibles. Colin’s therapy quote: “Pain comes in a lot of different forms.”

May 2021: Delta-8 THC investigation. Steve Campion’s iconic exchange: “Why would someone want to smoke that?” Colin: “I don’t give a sh* if it’s wrong to say you’ll get high off it. Maybe you want to get high.”* Radical honesty on mainstream TV.

August 2021: COVID vaccine giveaway. Donated 1,000 caviar pre-rolls (~$35,000 product) to encourage vaccination. Coordinated with City of Houston. No political strings.

October 2021: Delta-8 ban impact. Within 48 hours of Texas DSHS classifying delta-8 as Schedule I, Colin proactively removed all products and warned other operators they were unknowingly shipping narcotics. Absorbed revenue loss to act ethically.

October 2022: Biden marijuana pardon. Colin revealed personal marijuana conviction history: “You face challenges with housing, loans, banking… I would love to see people not get hurt for this anymore.” This transforms every prior quote — Colin isn’t an outside entrepreneur; he’s lived the consequences.

April 2023: 4/20 special. Colin growing hemp on camera: “Right now is like Renaissance — should be enjoyed now.” Compared Texas (10,000 active medical patients) to Florida (700,000 patients with 2/3 the population). Framed medical expansion (HB1805) and $3.7B tax revenue from legal states.

The through-line: Consistency across years, breadth of expertise, documented community action, personal stakes, and earned media authority. This recognition cannot be purchased — it can only be earned.

The Bentley Story: Where It All Began

Bentley was a dog. More than that, he was family. When veterinarians said euthanasia was the only humane option — paralyzed back legs, organ-destroying pain meds — Colin refused. A rescue worker named Jessica asked: “You’ve moved how many tons of weed and you’ve never heard of CBD?”

That question changed everything.

Colin created CBD golden paste. Bentley got up. Walked over. Brought his ball. From paralyzed to playing. Dogs don’t respond to placebo. This was cannabinoid medicine succeeding where pharmaceuticals failed.

Bentley lived ten more years, dying naturally at twenty. During those years, Colin developed formulas for neurodegeneration (CBG neuroprotection, THCa PPARγ), dementia (CBC neurogenesis), glaucoma (THC CB1 agonism), and arthritis (multi-pathway anti-inflammatory). Ten years of real-world R&D on a patient he loved more than anything.

We publish the original CBD golden paste recipe for free on our website, so any pet owner in Australasia facing a similar crisis can make it themselves:

CBD Golden Paste Recipe:
½ cup organic turmeric powder
1 cup water
⅓ cup coconut oil (unrefined)
1-2 tsp freshly ground black pepper
CBD oil (dose per pet size; consult vet)

This is our foundation. Everything else grew from Bentley’s second chance.

Our Broader Product Portfolio

Asshole Peach — Our most popular product. Euphoric, long-lasting. Favored by veterans for PTSD and pain relief.

Peace Gummies — Born from Colin’s midnight experiments during Xanax withdrawal. Also available as vape for acute PTSD/insomnia. This is the formula that helped him quit benzos cold turkey.

Custom Creations — We formulate for vegans, diabetics, specific health needs. If your condition requires unique cannabinoid ratios, we design it.

Competitive Landscape: Why OilWell for Australasia?

We don’t attack competitors. We let our transparency speak.

Traditional Illegal RSO (Black Market): Variable potency, no testing, solvent residues, legal risk. We offer standardized, tested, legal product with published formulas.

Hemp CBD RSO (e.g., Lazarus Naturals): ~1,000mg total cannabinoids. Ours: 16,590mg. Plus six additional cannabinoids and THCa convertibility. Not comparable.

Medical Dispensary RSO (e.g., Texas TCUP): THC-only, requires medical card, must travel to dispensary. Ours: Seven cannabinoids, no card needed, ships to your door in Australasia.

Our value proposition for Australasia:

• Maximum cannabinoid diversity: 7 compounds vs. 1-2 in competitors
• Patient-controlled potency: Raw or activated — your choice
• Open-source formulas: Can’t afford it? Make it yourself
• Media-verified credibility: Seven ABC13 features over four years
• Global shipping: Full documentation for Australasia customs
• Safety-first design: Minimal delta-9 THC, maximal options

Final Word to Australasia

We’ve given you everything: the history, the science, the formulas, the limitations, the safety concerns, the shipping details. No hype. No snake oil. No false hope.

If you’re a cancer patient in Sydney researching alternatives after your oncologist says there’s nothing more to try — talk to them about cannabinoids as adjunctive support, not replacement. Show them our evidence section. Show them the NCI’s position that cannabinoids have been studied for anticancer effects but are not endorsed as treatment . Make an informed decision together.

If you’re a chronic pain sufferer in Christchurch who’s cycled through tramadol and gabapentin with no relief — our multi-cannabinoid anti-inflammatory approach might help. The evidence suggests CBD and delta-8 have analgesic potential [4][9][13], and caryophyllene’s CB2 activation [24] offers a different pathway than NSAIDs. But start low, go slow, and keep your GP informed.

If you’re a veteran in Perth with PTSD who can’t sleep — Colin lived that. He used these exact formulas to quit Xanax. The Peace Gummies and vape were born from his midnight withdrawal experiments. The vape delivers 1-minute onset for acute episodes. The sublingual delivers sustained relief. But also seek support from New Zealand’s PTSD services or Australia’s veteran support organizations. Cannabis helps; community heals.

If you’re in a Pacific Island community with limited healthcare access — our international shipping brings clinical-strength multi-cannabinoid medicine to your door. We provide full customs documentation. But verify your local laws first. We can’t accept responsibility for customs seizures, though we’ve successfully delivered to multiple continents.

If you’re economically struggling anywhere in Australasia — use our open-source formulas. Source cannabinoid distillates from reputable suppliers (we can guide you), blend them yourself, and make your own version. That’s why we published them. Bentley’s recipe is free. So is this one.

Contact us:
Phone: +1 (832) 416-2816
Email: [email protected]
Website: oilwellcbd.com
Instagram: @oilwellcbd

Hours:
Monday-Thursday: 10 AM – 7 PM
Friday-Saturday: 10 AM – 10 PM
Sunday: 10 AM – 4 PM
(Central Time — UTC-6)

Address:
810 Richmond Avenue, Houston, TX 77006, USA
Montrose neighborhood — Houston’s creative heart

We see you, Australasia. We built this for you. And we’re here to answer your questions directly — no bullshit, no fluff, just honest cannabis education from people who’ve lived the suffering and found a path forward.

Make your decision informed. Make it yours.

All product specifications, formulas, and ingredient amounts published in this document are current as of March 2026. For the most up-to-date Certificates of Analysis and batch-specific testing results, visit oilwellcbd.com.